acide (cyanomethoxy)-imino-2 Z (tritylamino-2 thiazolyl-4)-2 acetique | 68672-55-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: acide (cyanomethoxy)-imino-2 Z (tritylamino-2 thiazolyl-4)-2 acetique
• 英文别名: (Z)-cyanomethoxyimino-(2-tritylamino-thiazol-4-yl)-acetic acid；2-(cyanomethyloxyimino)-2-(2-tritylamino-4-thiazolyl)-acetic acid；(2Z)-2-(cyanomethoxyimino)-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetic acid
• CAS: 68672-55-9
• 化学式: C₂₆H₂₀N₄O₃S
• 分子量: 468.536
• InChiKey: WXAZKFDZPUFDML-WMMMYUQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  acide (cyanomethoxy)-imino-2 Z (tritylamino-2 thiazolyl-4)-2 acetique 在 N-甲基吗啉 、 三乙基硅烷 、 palladium diacetate 、 三苯基膦 、 三氟乙酸 、 三氯氧磷 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 3.42h， 生成 LY210581
  参考文献：
  名称：

  Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters

  摘要：

  The structure-activity relationship among a series of novel pyrazolidinone antibacterial agents is described. Specifically, the effect of modification of the side chain attached to the nitrogen at C-7 was explored in an attempt to improve the potency and spectrum of activity. This approach was successful in identifying several compounds having good in vitro profiles. These top candidates were then evaluated for their activity in vivo, and their pharmacokinetic behavior in various animal models was explored. This information proved critical for the identification of candidates for clinical evaluation.

  DOI：

  10.1021/jm00074a002
• 作为产物：
  描述：

  cyanomethoxyimino-(2-tritylamino-thiazol-4-yl)-acetic acid cyanomethyl ester 生成 acide (cyanomethoxy)-imino-2 Z (tritylamino-2 thiazolyl-4)-2 acetique
  参考文献：
  名称：

  HEYMES, R.

  摘要：

  DOI：

文献信息

• Synthesis and antibacterial activity of lactivicin derivatives.
  作者：Norikazu TAMURA、Yoshihiro MATSUSHITA、Yasuhiko KAWANO、Kouichi YOSHIOKA

  DOI：10.1248/cpb.38.116

  日期：——

  chemical modification of the 4-acetylamino group on the cycloserine moiety of lactivicin (1a) was carried out. The lactivicin derivatives (1d, k--p and w) having heterocyclic acylamino groups which have been often utilized in beta-lactam antibiotics showed potent antibacterial activities. Ester prodrugs (7a--d) of lactivicin derivatives were also prepared in order to improve the bioavailability on oral administration

  对lactivicin（1a）的环丝氨酸部分上的4-乙酰氨基进行了化学修饰。具有杂环酰基氨基的lactivicin衍生物（1d，kp和w）通常在β-内酰胺类抗生素中使用，具有很强的抗菌活性。还制备了lactivicin衍生物的酯前药（7a-d），以提高口服给药的生物利用度。发现新戊酰氧基甲基（POM）酯（7a和7b）和1-乙氧基羰基氧基乙基（EOE）酯（7c）与它们的母体化合物1c和1k相比在体内的保护作用略有改善。
• Cephalosporin derivatives
  申请人：ICI PHARMA

  公开号：EP0127992A2

  公开（公告）日：1984-12-12

  A cephalosporin derivative of the formula I: in which X is S, 0, CH2 or SO. R1 is (optionally- substituted)imidazol-2-yl or one of the C-7 acyl groups known in the cephalosporin art, R2 is hydrogen or methoxy, R3 is carboxy or a biodegradiable ester thereof and -R4 is of the formula XII, XIII or XIV: R35 in which R32-R40 inclusive are as defined in the specification; and the salts thereof. Pharmaceutical compositions methods of manufacture and intermediates are also described.

  式 I 的头孢菌素衍生物： 其中 X 是 S、0、CH2 或 SO。R1 是（任选取代的）咪唑-2-基或头孢菌素领域已知的 C-7 乙酰基之一，R2 是氢或甲氧基，R3 是羧基或其生物降解酯，-R4 是式 XII、XIII 或 XIV： R35 其中 R32-R40 包括在内如说明书中所定义；及其盐类。还描述了药物组合物的制造方法和中间体。
• Cephalosporin compounds and salts thereof, their production, and medicaments containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0142274A2

  公开（公告）日：1985-05-22

  Antibacterial compounds of formula(I), and salts thereof: wherein the wavy line represents syn-form or anti-form bond; R' represents a cyanomethyl group, a thiocarbamoylmethyl group or an aminothiazolylmethyl group; and A represents where n is 1 or 2, R2 represents a hydrogen atom, a sulfo group, -(CH2)mCOOH, -(CH2)mOH, -(CH2)mNHR3, or -CONHR4 (where m represents 0 or an integer of 1 to 3, R3 represents a hydrogen atom oran acyl group, and R4 represents a carboxy alkyl group or a hydroxyl group).

  式(I)的抗菌化合物及其盐类： 其中波浪线代表同式键或反式键； R' 代表氰甲基、硫代氨基甲酰基或氨基噻唑甲基；以及 A 代表 其中 n 为 1 或 2、 R2 代表氢原子、磺基、-(CH2)mCOOH、-(CH2)mOH、-(CH2)mNHR3 或 -CONHR4（其中 m 代表 0 或 1 至 3 的整数，R3 代表氢原子或酰基，R4 代表羧基烷基或羟基）。
• Cephalosporin compounds and medicaments and their production
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0148007A2

  公开（公告）日：1985-07-10

  Antibacterial compounds of formula (I). wherein A represents a hydrogen atom, a carbamoyloxy group, (4-carboxy-3-hydroxytisothiazol-5-yl) thio group or a group shown by the formula : (wherein R' is a lower alkyl group); B represents a hydrogen atom -CH2OOC-C(R2)3 or a pharmaceutically acceptable cation for forming carboxylate salt; and R2 is a lower alkyl group.

  式(I)的抗菌化合物 其中 A 代表氢原子、氨基甲酰氧基、(4-羧基-3-羟基异噻唑-5-基)硫基或式(其中 R' 为低级烷基)所示的基团；B 代表氢原子-CH2OOC-C(R2)3 或药学上可接受的阳离子，用于形成羧酸盐；R2 为低级烷基。
• Cephalosporin compounds, their production, and pharmaceutical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0190900A2

  公开（公告）日：1986-08-13

  Novel cephalosporin compounds of the formula and sahs thereof, and some production methods thereof wherein R' represents a lower alkyl group which is unsub- situtted or substituted by a cyano group or a halogen atom, R2 represents a hydroxy lower alkyl group, a cyano group, a lower alkylthio group, a lower alkenyl group substitutable by carboxy, a lower alkinyl group, an imidazolyl group, a C3 to C6 alicyclic group, a 2-oxo-1, 3-dioxol-5-yl group, a 2-carboxy-I, 3-dithiolan-2-yl group, -CORA (wherein RA is an amino group, a pyridyl group, a carboxyl group, a C3 to Ce alicyclic group, a lower alkyl group which is unsubstituted or substituted by a halogen atom), or (wherein RB represents a lower alkyl group which is unsubstituted or substitued by a carboxyl group, RC represents a carboxyl group or a lower alkyl group), n represents an integer of 1 to 3; R3 represents a hydrogen atom or a lower alkyl group. These compounds have excellent antibacterial activities and are useful for the prevention and treatment of bacterial infections. The preparation and the use of these compounds as antibacterial agents is described.

  式中的新型头孢菌素化合物及其制备方法 其中，R'代表未被取代或被氰基或卤原子取代的低级烷基，R2 代表羟基低级烷基、氰基、低级烷硫基、可被羧基取代的低级烯基、低级烷基、咪唑基C3-C6脂环基、2-氧代-1, 3-二氧戊环-5-基、2-羧基-I, 3-二硫环戊-2-基、-CORA（其中 RA 是氨基、吡啶基、羧基、C3-Ce 脂环基、未被取代或被卤原子取代的低级烷基），或 (其中 RB 代表未被羧基取代或被羧基取代的低级烷基，RC 代表羧基或低级烷基），n 代表 1 至 3 的整数；R3 代表氢原子或低级烷基。这些化合物具有优异的抗菌活性，可用于预防和治疗细菌感染。本文介绍了这些化合物作为抗菌剂的制备和使用方法。